Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $129.8 million.

  • TScan Therapeutics' Shares Outstanding (Weighted Average) rose 938.12% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year increase of 938.12%. This contributed to the annual value of $112.0 million for FY2024, which is 7071.75% up from last year.
  • As of Q3 2025, TScan Therapeutics' Shares Outstanding (Weighted Average) stood at $129.8 million, which was up 938.12% from $129.7 million recorded in Q2 2025.
  • TScan Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $129.8 million during Q3 2025, with a 5-year trough of $1.2 million in Q1 2021.
  • For the 5-year period, TScan Therapeutics' Shares Outstanding (Weighted Average) averaged around $62.7 million, with its median value being $47.2 million (2023).
  • In the last 5 years, TScan Therapeutics' Shares Outstanding (Weighted Average) surged by 188386.67% in 2021 and then surged by 104.82% in 2023.
  • TScan Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $11.7 million in 2021, then skyrocketed by 106.2% to $24.0 million in 2022, then soared by 172.78% to $65.6 million in 2023, then surged by 70.72% to $112.0 million in 2024, then grew by 15.93% to $129.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $129.8 million in Q3 2025, compared to $129.7 million in Q2 2025 and $129.7 million in Q1 2025.